RxDoctor Payments Data

Ramon Martinez, MD

Psychiatry · Orlando, FLNPI 1457376964

Payments from drug & device makers

$353,737in general payments, 2019–2025

Across 1,048 payments — averaging $337.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$160K
  • Neurocrine Biosciences, Inc.$106K
  • Axsome Therapeutics, Inc.$18K
  • Sunovion Pharmaceuticals Inc.$16K
  • Takeda Pharmaceuticals U.S.A., Inc.$15K
  • AbbVie$14K
  • plus $26K from 33 others

What the payments were for

  • Consulting fees$41,31312%
  • Speaking & faculty fees$261,25574%
  • Travel & lodging$24,4897%
  • Food & beverage$26,3497%
  • Education$3300%
  • Gifts$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$353,737 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$74,004
Medicare patients
147
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate38$310,066
AustedoDeutetrabenazine20$135,288
Austedo XrDeutetrabenazine17$92,366
Lurasidone Hcl99$67,611
VraylarCariprazine Hcl35$47,651
ZyprexaOlanzapine17$46,647
TrintellixVortioxetine Hydrobromide57$33,611
RexultiBrexpiprazole11$18,499
AuvelityDextromethorphan Hbr/Bupropion15$14,457
Aripiprazole87$12,381
BelsomraSuvorexant28$11,973
PristiqDesvenlafaxine Succinate13$5,340
Clonazepam638$5,331
Clozapine46$5,083
Fluphenazine Hcl27$4,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$105,514$310,06638 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$160,134$227,65337 claims
Lilly USA, LLCZyprexa, Olanzapine$12$48,14185 claims
AbbVieVraylar$13,864$47,65135 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14,615$33,61157 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,937$18,49911 claims
Axsome Therapeutics, Inc.Auvelity$17,629$14,45715 claims
MerckBelsomra$61$11,97328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →